What is Aura?
Aura Biosciences is a pioneering biotechnology firm focused on the development of virus-like drug conjugates (VDCs). This novel technology platform is engineered to selectively target and destroy malignant cells while simultaneously stimulating the immune system to foster durable anti-tumor immunity. By operating at the intersection of oncology and immunology, Aura Biosciences occupies a critical niche in the life sciences landscape, aiming to redefine standard-of-care protocols for patients with high unmet medical needs. The company's strategic positioning is supported by a diverse syndicate of investors who provide both financial backing and deep domain expertise in therapeutic innovation.
How much funding has Aura raised?
Aura has raised a total of $345.9M across 13 funding rounds:
Private Equity
$4M
Series B
$21M
Debt
$11.5M
Series C
$30M
Series D
$40M
Other Financing Round
$80M
Stock Offering
$76M
Stock/Share Issuance
$69.9M
Private Equity (2014): $4M, investors not publicly disclosed
Series B (2015): $21M led by LI-COR Biosciences, Advent Life Sciences, Ysios Capital, and Chiesi Ventures
Debt (2016): $11.5M supported by Alexandria Venture Investments, Ysios Capital, and Chiesi Ventures
Series C (2017): $30M featuring Advent Life Sciences, The estate of Henri Termeer, Alexandria Venture Investments, Columbus Venture Partners SGEIC, Lundbeckfonden Ventures, Arix Bioscience, Chiesi Ventures, LI-COR Biosciences, and Ysios Capital
Series D (2019): $40M backed by Medicxi
Other Financing Round (2021): $80M with participation from Advent Life Sciences, Columbus Venture Partners S.G.E.I.C, Rock Springs Capital, Chiesi Ventures, Medicxi, Adage Capital Management, Matrix Capital Management, Lundbeckfonden Ventures, Arix Bioscience, Surveyor Capital, Velosity Capital, and Ysios Capital
Stock Issuance/Offering (2021): $76M, investors not publicly disclosed
Stock/Share Issuance (2025): $69.9M, investors not publicly disclosed
Key Investors in Aura
Ysios Capital
A leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide, providing resources to ventures focused on high unmet medical needs.
Chiesi Ventures
A venture capital firm dedicated to investing in early-stage development opportunities focused on rare and orphan disorders, collaborating with global partners to accelerate R&D.
Advent Life Sciences
A specialized venture capital and private equity firm with a strong focus on the life sciences sector, providing strategic guidance to emerging biotech companies.
What's next for Aura?
With the infusion of this latest capital, Aura Biosciences is well-positioned to accelerate its clinical development programs and scale its operational capabilities. The company is expected to prioritize the advancement of its VDC platform through late-stage trials, aiming to validate the efficacy and safety of its lead candidates. As the firm transitions into a more mature phase of its lifecycle, the focus will likely shift toward regulatory milestones and potential commercialization strategies. Continued support from its established investor base will be instrumental in navigating the complexities of the oncology market and achieving the firm's long-term objective of delivering transformative healthcare solutions.
See full Aura company page
